Drug Trial Radar · NCT04011293
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies
Last checked: Nov 19, 2026Latest source record: Jul 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Jul 2019
Primary completion
Jul 2020
Study completion Apr 2022
Sponsor
- Lead sponsor
- Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Juventas Cell Therapy Ltd.
- First posted
- Jul 8, 2019
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single arm, open-label, single center study to determine the safety and efficacy of CNCT19 in adult patients with Relapsed or Refractory B cell Malignancies.
Conditions
- Relapsed or Refractory Hematological Malignancies
Interventions
CNCT19Biological
0.5 to 4 x 10\^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: 24 months
- Overall remission rate (ORR)Time frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.